NexImmune, Inc. has filed a Notification of Late Filing with the SEC, indicating that its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, will be delayed. The company attributes the delay to a significant reduction in workforce, which has left it with fewer resources to prepare and review the financial statements. Despite the reduction, key management and scientific team members remain to support ongoing business efforts. NexImmune expects to file the Form 10-K within the fifteen-day extension period allowed under Rule 12b-25 of the Securities Exchange Act. The company has also included forward-looking statements in the notification, cautioning that actual results may differ from current expectations due to risks and uncertainties. The notification was signed by CEO Kristi Jones on March 29, 2024.

NexImmune, Inc. has filed a Notification of Late Filing with the SEC, indicating that its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, will be delayed. The company attributes the delay to a significant reduction in workforce, which has left it with fewer resources to prepare and review the financial statements. Despite the reduction, key management and scientific team members remain to support ongoing business efforts. NexImmune expects to file the Form 10-K within the fifteen-day extension period allowed under Rule 12b-25 of the Securities Exchange Act. The company has also included forward-looking statements in the notification, cautioning that actual results may differ from current expectations due to risks and uncertainties. The notification was signed by CEO Kristi Jones on March 29, 2024.